NCT03145558 (TATE) is a Phase 2 clinical trial of Tirapazamine in Carcinoma, Hepatocellular, sponsored by Teclison Ltd..

Who is sponsoring NCT03145558?

NCT03145558 is sponsored by Teclison Ltd..

What drugs are being tested in NCT03145558?

Interventions in NCT03145558: Tirapazamine, Doxorubicin.

What condition does NCT03145558 study?

NCT03145558 studies Carcinoma, Hepatocellular.

Is NCT03145558 still recruiting?

NCT03145558 is currently terminated. Last updated 22 November 2024.

Last reviewed 2024-11-22 · How we verify

NCT03145558: TATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TATE Versus TACE in Intermediate Stage HCC

Terminated Phase 2 Last updated 22 November 2024

What this trial tests

Phase 2 trial testing Tirapazamine in Carcinoma, Hepatocellular in 6 participants. Terminated before completion.

Timeline

5 December 2017

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Teclison Ltd.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	6
Start date	5 December 2017
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	3 locations across United States

Drugs / interventions tested

Tirapazamine — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Teclison Ltd. — full company profile →

Who can join

Adults 18 to 85, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation. The primary endpoint is Progression Free Survival. Secondary endpoints including CR rate, Time to embolization failure, Duration of CR, OS, ORR, local control rate, time to local recurrence and duration to local recurrence. The study treatment is to compare Tirapazamine versus doxorubicin when combined with trans-arterial embolization. Study plans to enroll 134 patients in 1:1 randomization for TATE or TACE. MRI will be used to assess efficacy using a central radiological review for the final analysis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Interfering with Tumor Hypoxia for Radiotherapy Optimization.
Telarovic I, Wenger RH, Pruschy M. · · 2021 · cited 119× · PMID 34154610 · DOI 10.1186/s13046-021-02000-x
Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma.
Huynh KN, Rao S, Roth B, Bryan T, et al · · 2023 · cited 24× · PMID 37345074 · DOI 10.3390/cancers15102738
Targeting Hypoxia: Revival of Old Remedies.
Vilaplana-Lopera N, Besh M, Moon EJ. · · 2021 · cited 9× · PMID 34827602 · DOI 10.3390/biom11111604

Verify or expand the search:

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Other Teclison Ltd. trials

Trials by the same sponsor.

NCT04701476 — TATE and Pembrolizumab (MK3475) in mCRC and NSCLC · Phase 2 · recruiting
NCT03259867 — Combination of TATE and PD-1 Inhibitor in Liver Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03145558 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Teclison Ltd.
Last refreshed: 22 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03145558.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing